It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Objective: To compare adverse pregnancy outcomes, namely low birth weight, low Apgar scores at 1 and 5 minutes, extremely low Apgar scores at 1 and 5 minutes, and preterm delivery between thalassaemia carriers and healthy controls.
Methods: A retrospective review of all pregnancies delivered in a public hospital in Hong Kong in which routine thalassaemia screening was performed at the booking visit was conducted. The obstetric database and medical records from 1 July 2010 to 31 December 2011 were reviewed. Adverse obstetric outcomes between pregnant women who were thalassaemia carriers and healthy controls were compared. Outcomes of interest included low birth weight, low Apgar score at birth, and preterm delivery. Independent paired t test was used to analyse parametric data and Chi-square or Fisher’s exact tests were used to analyse non-parametric data.
Results: A total of 7661 deliveries with valid data were identified during the study period, of which 287 (3.7%) occurred in thalassaemia carriers. Among the 287 thalassaemia carriers, 159 (55.4%), 107 (37.3%), and 21 (7.3%) were found to have α, β, and other haemoglobinopathy, respectively. Anaemia occurred in 6.2% (472/7620) of deliveries for which anaemia data were available. No significant differences in low birth weight (p=0.74), low Apgar scores at 1 minute (p=0.66) and 5 minutes (p=0.72), or preterm delivery (p=0.83) were noted between thalassaemia carriers and healthy controls. However, anaemia in pregnancy was significantly associated with adverse perinatal outcome, including low birth weight (p=0.03), low Apgar scores at 1 minute (p=0.02) and 5 minutes (p=0.04), and preterm delivery (p=0.02).
Conclusion: In general, the course of pregnancy of thalassaemia carriers was favourable without significant adverse perinatal outcomes. However, adverse outcomes were associated with anaemia. We recommend vigilant investigation, treatment, and prevention of anaemia to improve pregnancy outcomes.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer